Effects of moxifloxacin ophthalmic: A Synthesis of Findings from 17 Studies

  1. Home
  2. Effects of moxifloxacin ophthalmic
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of moxifloxacin ophthalmic: A Synthesis of Findings from 17 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of moxifloxacin ophthalmic: A Synthesis of Findings from 17 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Moxifloxacin ophthalmic solution has been shown to be effective in treating various eye infections, including bacterial conjunctivitis, endophthalmitis and keratitis. 12 , 8 , 9 . This is because moxifloxacin, a fourth-generation fluoroquinolone, is specifically designed to combat the increasing resistance against earlier-generation antibiotics. 12 . Moxifloxacin boasts superior efficacy against gram-positive bacteria compared to its predecessors, while maintaining excellent potency against gram-negative bacteria and non-tuberculous (atypical) mycobacteria. 12 . This enhanced activity is further aided by moxifloxacin’s unique molecular structure, which leads to improved bioavailability and corneal penetration. 12 .

Studies have demonstrated that moxifloxacin ophthalmic solution exhibits high potency against a broad spectrum of microbial species and possesses a favorable safety profile. 12 , 13 . This makes it a promising candidate for surgical prophylaxis and treatment of sight-threatening infections. 12 , 8 . Furthermore, the pharmacokinetics of moxifloxacin are not significantly influenced by age or gender. 1 . However, the absorption of moxifloxacin may be reduced if taken concurrently with certain medications like iron supplements or sucralfate. 3 , 2 .

Research on moxifloxacin's safety has extended beyond human trials, with animal studies and in vitro experiments demonstrating favorable results. 10 . Moxifloxacin exhibits a low risk of quinolone-related toxicity compared to other fluoroquinolones. 10 .

Benefits and Risks

Benefits Summary

Moxifloxacin ophthalmic solution shows promise as an effective treatment for various eye infections, particularly those caused by bacteria, such as bacterial conjunctivitis, endophthalmitis and keratitis. 12 , 8 , 9 . This effectiveness stems from its ability to combat bacterial resistance and its unique molecular structure which contributes to better bioavailability and corneal penetration. 12 .

Risks Summary

Moxifloxacin ophthalmic solution is generally considered safe and well-tolerated. 12 . However, like all medications, there is a risk of side effects. 9 . The most common side effect is temporary eye discomfort, which occurs at a similar rate to placebo. 9 . It's important to note that prolonged or high-dose use of moxifloxacin ophthalmic solution might have adverse effects on corneal endothelial cells, making adherence to medical instructions crucial. 10 . Additionally, the absorption of moxifloxacin can be impacted by co-administration of certain medications like iron supplements or sucralfate. 3 , 2 . Always consult a doctor before using moxifloxacin ophthalmic solution and ensure you understand the proper usage and potential side effects.

Comparison Between Studies

Commonalities

Research consistently points towards moxifloxacin ophthalmic solution’s efficacy in treating various eye infections, including bacterial conjunctivitis, endophthalmitis and keratitis. 12 , 8 , 9 , 17 . Moxifloxacin exhibits superior efficacy compared to other ophthalmic solutions. 7 , 6 , 5 .

Differences

The research on moxifloxacin ophthalmic solution employs varying methodologies, including different application methods and evaluation parameters. 12 , 8 , 9 , 17 . Therefore, it’s crucial to account for these differences when comparing findings. 7 , 6 , 5 .

Consistency and Contradictions

Several studies converge in suggesting that moxifloxacin ophthalmic solution is a beneficial treatment for various eye infections. 12 , 8 , 9 , 17 . However, the findings on moxifloxacin’s safety show some discrepancies across different studies. 10 . Consequently, when using moxifloxacin ophthalmic solution, it’s vital to consult a doctor and ensure you understand the proper usage and potential side effects. 10 .

Real-Life Applications and Considerations

Moxifloxacin ophthalmic solution has demonstrated effectiveness in treating eye infections, including bacterial conjunctivitis, endophthalmitis and keratitis. 12 , 8 , 9 , 17 . However, it’s not a universal solution for all eye infections. 14 . Additionally, moxifloxacin ophthalmic solution can interact with other medications. 3 , 2 . Therefore, consulting a doctor before using moxifloxacin ophthalmic solution and ensuring you understand the proper usage and potential side effects is crucial. 10 .

Limitations of Current Research

There is a need for further research on moxifloxacin ophthalmic solution. 10 . This includes exploring its long-term effects, its impact on various age groups and body types, and its interactions with other medications. 10 , 3 , 2 .

Future Research Directions

Further research on moxifloxacin ophthalmic solution is crucial to gain a more comprehensive understanding of its efficacy and safety. 10 . This research should address its long-term effects, its impact on various age groups and body types, and its interactions with other medications. 10 , 3 , 2 .

Conclusion

Moxifloxacin ophthalmic solution holds promise as an effective treatment for a range of eye infections, particularly those caused by bacteria. 12 , 8 , 9 , 17 . However, it’s essential to consult a doctor before using moxifloxacin ophthalmic solution and ensure you understand the proper usage and potential side effects. 10 . Moxifloxacin ophthalmic solution shows potential in treating many eye infections, but further research is vital to solidify its safety and efficacy. 10 .

Literature analysis of 17 papers
Positive Content
13
Neutral Content
0
Negative Content
4
Article Type
6
0
0
5
17
1.

The influence of age and gender on the pharmacokinetics of moxifloxacin.

Author: SullivanJ T, LettieriJ T, LiuP, HellerA H

Antibacterial effects
Reduced bioavailability

Moxifloxacin does not exhibit age- or gender-dependent pharmacokinetics. Oral doses of 200 to 400mg yield effective antibacterial concentrations on the first day of administration.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.

Author: StassH, SchühlyU, MöllerJ G, DelesenH

Reduced bioavailability

Concomitant administration of sucralfate and moxifloxacin significantly reduced the bioavailability of moxifloxacin. This reduction in bioavailability is likely due to a chelation reaction with polyvalent cations, which is a common finding for quinolones. Therefore, staggered administration of moxifloxacin and Al3+-containing interactants should be considered to avoid subtherapeutic plasma concentrations of the quinolone.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans.

Author: StassH, KubitzaD

Reduced bioavailability

Concomitant administration of iron supplements and moxifloxacin significantly reduced the bioavailability of moxifloxacin. This reduction in bioavailability is likely due to a chelation reaction with polyvalent cations, which is a common finding for quinolones. Therefore, staggered administration of moxifloxacin and iron supplements should be considered to avoid subtherapeutic plasma concentrations of the quinolone.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

4.

Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects.

Author: TaubelJorg, FerberGeorg, LorchUlrike, BatchvarovVelislav, SavelievaIrina, CammA John

Reduced QT prolongation
QT prolongation

This study investigated the effect of food on the QT prolongation caused by moxifloxacin in a TQT study and compared the QTc F profile of oral moxifloxacin in Japanese and Caucasian volunteers.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

5.

The effects of moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3% treatment on corneal wound healing in pigmented rabbits following anterior keratectomy.

Author: WilliamsK Keven, McCartneyMitchell D, RiceRebecca L, WaxMartin B, HiddemenJoseph W

Corneal healing

This study examined corneal healing rates and protein expression in pigmented rabbits treated with moxifloxacin 0.5%, gatifloxacin 0.3%, or balanced salt solution (BSS) after anterior keratectomy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Comparison of the effects of fourth-generation fluoroquinolones on corneal re-epithelialization in rabbit eyes.

Author: MoshirfarMajid, ChewJesse, WernerLiliana, MeyerJay J, HunterBrian, StevensScott, JensenMike, KleinmannGuy, MamalisNick

Wound healing interference

Gatifloxacin, a topical antibiotic preserved with benzalkonium chloride, was found to have a negative impact on corneal re-epithelialization in rabbits compared to unpreserved moxifloxacin. This suggests that unpreserved antibiotics may be preferable for post-surgical corneal healing.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Corneal wound healing in New Zealand White Rabbits following anterior keratectomy and treatment with moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3%.

Author: WilliamsK Keven, ShepardAllan R, RiceRebecca L, McCartneyMitchell D, WaxMartin B, HiddemenJoseph W

Corneal reepithelialization

This study found that there were no significant differences in corneal reepithelialization rates and type IV collagen expression between moxifloxacin ophthalmic solution 0.5%, gatifloxacin ophthalmic solution 0.3%, and a commercially available irrigating solution in a rabbit anterior keratectomy model.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).

Author: SchlechBarry A, AlfonsoEduardo

Antibiotic resistance reduction
Ocular infection treatment

The fourth-generation ophthalmic fluoroquinolones include moxifloxacin (VIGAMOX, Alcon Laboratories, Inc., Fort Worth, TX) and gatifloxacin (Zymar, Allergan, Irvine, CA), and they are now approved for the treatment of bacterial conjunctivitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis.

Author: SilverLewis H, WoodsideAdrienne M, MontgomeryDawnelle B

Bacterial conjunctivitis treatment
Ocular discomfort

Moxifloxacin ophthalmic solution 0.5% is safe and well tolerated in pediatric (3 days-17 years of age) and nonpediatric (18-93 years) patients with bacterial conjunctivitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Safety of moxifloxacin as shown in animal and in vitro studies.

Author: McGeeDavid H, HoltWilliam F, KastnerPhilip R, RiceRebecca L

Ocular infection treatment

Moxifloxacin ophthalmic solution 0.5% provides antibacterial potency and high penetration of target ocular tissues. It is safe and well tolerated in patients with bacterial conjunctivitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.

Author: StromanDavid W, DajcsJoseph J, CuppGale A, SchlechBarry A

Antibiotic resistance reduction
Ocular infection treatment

The fourth-generation fluoroquinolones, such as moxifloxacin and gatifloxacin, have enhanced activity against gram-positive bacteria while retaining potent activity against most gram-negative bacteria.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

12.

Ophthalmic infections and their anti-infective challenges.

Author: AlfonsoEduardo, CriderJulie

Antibiotic resistance reduction
Ocular infection treatment

Moxifloxacin ophthalmic solution 0.5% has high potency against a broad range of microbial species and a favorable profile in terms of safety and tolerability.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

13.

Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor.

Author: KatzHarold R, MasketSamuel, LaneStephen S, SallKenneth, OrrSusan C, FaulknerRobert D, McCueBette A, DahlinDavid C

Endophthalmitis prevention
Moxifloxacin absorption

Topical moxifloxacin was well absorbed into the aqueous humor after administration of moxifloxacin hydrochloride ophthalmic solution. Maximum moxifloxacin concentrations were approximately 30 times higher than the median MICs for common pathogens in bacterial endophthalmitis, indicating that either regimen may provide sufficient concentrations to prevent postoperative endophthalmitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.

Author: TorkildsenGail, O'BrienTerrence P

Treat acute eye disease
Treat chronic eye disease

This study highlights the importance of determining specific tissue concentrations and residence times of antibacterial agents in ocular tissues for effective treatment of both acute and chronic diseases.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.

Author: CalleganMichelle C, NovosadBilly D, RamadanRaniyah T, WiskurBrandt, MoyerAndrea L

Antibacterial activity

The antibacterial activity of ophthalmic fourth-generation fluoroquinolones was compared, revealing that the presence of benzalkonium chloride (BAK) in gatifloxacin ophthalmic solution significantly affects its antibacterial activity compared to preservative-free moxifloxacin ophthalmic solution.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.